Global Biosimilars Market (2022 Edition) - Analysis By Product Type, Application, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028)

The Global Biosimilars Market was valued at USD 16.48 Billion in the year 2021 with the Europe region leading the regional market share. One of the main factors driving this market is the expiration of patents of major pharmaceutical drugs and thus the opportunity to develop more biosimilar drugs.

Additionally, Biosimilars are priced way lower than their reference counterparts, with the increasing burden of health expenditure. Biosimilars provide relief to the healthcare infrastructure of several developing countries and are anticipated to impel market growth in the forecast period.

The Asia Pacific is the fastest growing market in the biosimilars market as countries within the region are providing opportunities to grow and sell medicines. The growing initiatives of the government and increasing investment in healthcare are providing rapid growth.

The FDA reported the shortage of drugs during COVID-19 due to a lack of API and disruptions in the supply chain market. The higher rate of competition in the biosimilar market led to the growth of biologics having long-term supplies. A longer time for approvals was occurring due to a delay in the inspection of the manufacturing facility. The delivery of products is also the major concern impacting the market of biosimilars apart from product manufacturing.

Scope of the Report

The report presents the analysis of Biosimilars Market for the historical period of 2018-2021, estimates for 2022 and the forecast period of 2023-2028.
The report analyses the Biosimilars Market by Value (USD Million).
The report analyses the Biosimilars Market by Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin Others).
The report analyses the Biosimilars Market by Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases, Others).
The Global Biosimilars Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The Global Biosimilars Market has been analysed By Country (United States, Canada, Germany, U.K, France, Italy, Spain, China, Japan, India).
The key insights of the report have been presented through the leading company shares. Also, the attractiveness of the market has been presented by region, by Product Type and by End User.
Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
The report tracks competitive developments, strategies, and recent developments. The companies analysed in the report include Pfizer, Dr.Reddy's Laboratories, Amgen, Novartis AG, Teva Pharmaceuticals Ltd., Samsung Biologics, Eli lilly and company, Stada Arzneimittel, Celltrion, Biocon Limited.

Key Target Audience

Biosimilar Companies
Pharmaceutical and Healthcare Companies
End Users (Hospitals, Ambulatory Surgical Centres, Research & Laboratories)
Research and Development (R&D) Organizations
Government Bodies & Regulating Authorities
Investment Banks and Equity Firms

1. Report Scope and Methodology

1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary

2. Strategic Recommendations

3. Global Biosimilars Market: Product Overview

4. Global Biosimilars Market: An Analysis

4.1. Assessment of Macro Economic Indicators of Global Biosimilars Market
4.2 Global Biosimilars Market, Market Size, By Value, 2018-2028
4.3 Global Biosimilars Market: Growth and Forecast
4.4 Impact of COVID-19 on Global Biosimilars Market

5. Global Biosimilars Market: Segment Analysis

5.1 Global Biosimilars Market Segmentation, By Product Type
5.2 Competitive Positioning of Biosimilars Market: By Product Type (2021 & 2028)
5.3 By Monoclonal antibodies, By Value (USD Billion), 2018-2028
5.4 By Filgrastim and Pegfilgrastim, By Value (USD Billion), 2018-2028
5.5 By Insulin, By Value (USD Billion), 2018-2028
5.6 By Others, By Value (USD Billion), 2018-2028

6. Global Biosimilars Market: Segment Analysis By Application

6.1 Global Biosimilars Market Segmentation, By Application
6.2 Competitive Positioning of Global Biosimilars Market, By Application (2021 & 2028)
6.3 By Oncology, By value (USD Billion), 2018-2028
6.4 By Chronic and Autoimmune Diseases, By value (USD Billion), 2018-2028
6.5 By Blood Disorders, By value (USD Billion), 2018-2028
6.6 By Infectious Diseases , By Value (USD Billion), 2018-2028
6.7 By Others, By Value (USD Billion), 2018-2028

7. Global Biosimilars Market: Regional Analysis

7.1 Competitive Positioning of Global Biosimilars Market: By Region (2021 & 2028)

8. Americas Biosimilars Market: An Analysis (2018-2028)

8.1 Assessment of Macro Economic Indicators of Americas Biosimilars Market
8.2 Americas Biosimilars Market- Size and Forecast, By Value (2018-2028)
8.3 Americas Biosimilars Market: Prominent Companies
8.4 Americas Biosimilars Market: Segment Analysis
8.5 Americas Biosimilars Market By Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others)
8.6 Americas Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others)
8.7 Americas Biosimilars Market: Country Analysis
8.8 Market Opportunity Chart of Americas Biosimilars Market - By Country, By Value (Year-2028)
8.9 Competitive Positioning of Americas Biosimilars Market - By Country
8.10 United States Biosimilars Market: Size and Forecast, By Value (2018-2028)
8.11 United States Biosimilars Market By Product Type and By Application, By Value (2018-2028)
8.12 Canada Biosimilars Market: Size and Forecast, By Value (2018-2028)
8.13 Canada Biosimilars Market By Product Type and By Application, By Value (2018-2028)

9. Europe Biosimilars Market: An Analysis (2018-2028)

9.1 Assessment of Macro Economic Indicators of Asia Pacific Biosimilars Market
9.2 Europe Biosimilars Market- Size and Forecast, By Value (2018-2028)
9.3 Europe Biosimilars Market: Prominent Companies
9.4 Europe Biosimilars Market: Segment Analysis
9.5 Europe Biosimilars Market By Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others), By Value, 2018-2028
9.6 Europe Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others), By Value, 2018-2028
9.7 Europe Biosimilars Market: Country Analysis
9.8 Market Opportunity Chart of Europe Biosimilars Market - By Country, By Value (Year-2028)
9.9 Competitive Positioning of Europe Biosimilars Market - By Country
9.10 Germany Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.11 Germany Biosimilars Market By Product Type and By Application, By Value (2018-2028)
9.12 United Kingdom Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.13 United Kingdom Biosimilars Market By Product Type and By Application, By Value (2018-2028)
9.14 France Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.15 France Biosimilars Market By Product Type and By Application, By Value (2018-2028)
9.16 Italy Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.17 Italy Biosimilars Market By Product Type and By Application, By Value (2018-2028)
9.18 Spain Biosimilars Market: Size and Forecast, By Value (2018-2028)
9.19 Spain Biosimilars Market By Product Type and By Application, By Value (2018-2028)

10. Asia Pacific Biosimilars Market: An Analysis (2018-2028)

10.1 Assessment of Macro Economic Indicators of Asia Pacific Biosimilars Market
10.2 Asia Pacific Biosimilars Market- Size and Forecast, By Value (2018-2028)
10.3 Asia Pacific Biosimilars Market: Prominent Companies
10.4 Asia Pacific Biosimilars Market: Segment Analysis
10.5 Asia Pacific Biosimilars Market By Product Type, (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others)
10.6 Asia Pacific Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others), By Value
10.7 Asia Pacific Biosimilars Market: Country Analysis
10.8 Market Opportunity Chart of Asia Pacific Biosimilars Market - By Country, By Value (Year-2028)
10.9 Competitive Positioning of Asia Pacific Biosimilars Market - By Country
10.10 China Biosimilars Market: Size and Forecast, By Value (2018-2028)
10.11 China Biosimilars Market By Product Type and By Application, By Value (2018-2028)
10.12 Japan Biosimilars Market: Size and Forecast, By Value (2018-2028)
10.13 Japan Biosimilars Market By Product Type and By Application, By Value (2018-2028)
10.14 India Biosimilars Market: Size and Forecast, By Value (2018-2028)
10.15 India Biosimilars Market By Product Type and By Application, By Value (2018-2028)

11. MEA Biosimilars Market

11.1 Assessment of Macro Economic Indicators of MEA Biosimilars Market
11.2 MEA Biosimilars Market- Size and Forecast, By Value (2018-2028)
11.3 MEA Biosimilars Market By Product Type, (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others)
11.4 MEA Biosimilars Market By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases and Others), By Value

12. Global Biosimilars Market Dynamics

12.1 Global Biosimilars Market Drivers
12.2 Global Biosimilars Market Restraints
12.3 Global Biosimilars Market Trends

13. Market Attractiveness and Strategic Analysis

13.1 Market Attractiveness Chart of Global Biosimilars Market - By Product Type (Year 2028)
13.2 Market Attractiveness Chart of Global Biosimilars Market - By Application (Year 2028)
13.3 Market Attractiveness Chart of Global Biosimilars Market - By Region (Year 2028)

14. Competitive Landscape

14.1 Market Share of global leading companies
14.2 Recent Developments and Mergers & Acquisitions

15. Company Profiles (Business Description, Financial Analysis, Business Strategy)

15.1 Pfizer
15.2 Dr.Reddy's Laboratories
15.3 Amgen
15.4 Novartis AG
15.5 Teva Pharmaceuticals Ltd.
15.6 Samsung Biologics
15.7 Eli lilly and company
15.8 Stada Arzneimittel
15.9 Celltrion
15.10 Biocon Limited

List of Figures

Figure 1: Global GDP per capita (2018-2020) In USD Thousands
Figure 2: Global Aged Population (Above 65), 2017-21 (% of total Population)
Figure 3: Global Aged Population(Above 65), By Country, 2021 (% of total Population, roundoff)
Figure 4: Global Medical Spending in 2020, By Region, (% of Total)
Figure 5: Global Prevalence of Cardiovascular Diseases, (in million), 2015-2019
Figure 6: Current Healthcare Expenditure (% Share of GDP), By Selected Country, 2016-2020 (In %)
Figure 7: Global Expected Healthcare Industry Outlook
Figure 8: Regional Expected Healthcare Industry Growth Rate By Year 2024
Figure 9: Global Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 10: Global Biosimilars Market- By Product Type Market Share, 2021 & 2028
Figure 11: Global Biosimilars Market- By Product Type, By Monoclonal antibodies, By Value (USD Billion), 2018-2028
Figure 12: Global Biosimilars Market- By Product Type, By Filgrastin and Pegfilgrastin, By Value (USD Billion), 2018-2028
Figure 13: Global Biosimilars Market- By Product Type, By Insulin, By Value (USD Billion), 2018-2028
Figure 14: Global Biosimilars Market- By Product Type, By Others, By Value (USD Billion), 2018-2028
Figure 15: Global Biosimilars Market - By Application Market Share, 2021 & 2028
Figure 16: Global Biosimilars Market- By Application, By Oncology, By Value (USD Billion), 2018-2028
Figure 17: Global Biosimilars Market- By Application, By Chronic and Auto-immune diseases, By Value (USD Billion), 2018-2028
Figure 18: Global Biosimilars Market- By Application, By Blood Diseases, By Value (USD Billion), 2018-2028
Figure 19: Global Biosimilars Market- By Application, By Infectious diseases, By Value (USD Billion), 2018-2028
Figure 20: Global Biosimilars Market- By Application, By Others, By Value (USD Billion), 2018-2028
Figure 21: Global Biosimilars Market- By Region Market Share, 2021 & 2028
Figure 22: Americas Population (in Millions), 2018-2021
Figure 23: North America Population ages 65 and above (% of total Population), 2017-21
Figure 24: Latin America & Caribbean Population ages 65 and above (% of total Population), 2017-21
Figure 25: Current health expenditure per capita in the U.S. and Canada (current USD), 2020
Figure 26: Prevalence of Cardiovascular Diseases in Americas, (in million), 2015-2019
Figure 27: Americas Diabetes Prevalence, By Country, 2021 (in million)
Figure 28: Prevalence of Cancer in the Region of Americas(In Millions), 2015-2019
Figure 29: Americas Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 30: Americas Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 31: Americas Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 32: Market Opportunity Chart of Americas Biosimilars Market- By Country, By Value (Year-2028)
Figure 33: Americas Biosimilars Market- By Country Market Share, 2021 & 2028
Figure 34: United States Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 35: United States Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 36: United States Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 37: Canada Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 38: Canada Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 39: Canada Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 40: European Union Population (in Millions), 2018-2021
Figure 41: Population ages 65 and above(% of total Population) in European Countries, 2020
Figure 42: European Union Current health expenditure per capita (current USD), 2015-19
Figure 43: Country wise healthcare expenditure in Europe (% of GDP), 2020
Figure 44: European Union GDP Per Capita, value (USD Billion), 2018-20
Figure 45: Europe Prevalence of Cancer (in Million), 2015-2019
Figure 46: Europe Diabetes Prevalence, By Country, 2021 (in million)
Figure 47: Europe Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 48: Europe Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 49: Europe Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 50: Market Opportunity Chart of Europe Biosimilars Market- By Country, By Value (Year-2028)
Figure 51: Europe Biosimilars Market- By Country Market Share, 2021 & 2028
Figure 52: Italy Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 53: Italy Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 54: Italy Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 55: Germany Kingdom Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 56: Germany Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 57: Germany Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 58: France Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 59: France Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 60: France Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 61: United Kingdom Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 62: United Kingdom Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 63: United Kingdom Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 64: Spain Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 65: Spain Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 66: Spain Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 67: Asia Pacific, Population ages 65 and above (% of total Population), 2016-20
Figure 68: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Figure 69: Asia Pacific Current health expenditure per capita (current USD), 2014-18
Figure 70: Asia Pacific, Current health expenditure per capita, by countries (current USD), 2019
Figure 71: East Asia and Pacific Population (in Billion), 2018-2020
Figure 72: Prevalence of Total Cancer in Asia, (in million), 2015-2019
Figure 73: Asia Pacific Diabetes Prevalence, By Country, 2020 (% of Population Age 20 to 79)
Figure 74: Asia Pacific Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 75: Asia Pacific Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 76: Asia Pacific Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 77: Market Opportunity Chart of Europe Biosimilars Market- By Country, By Value (Year-2028)
Figure 78: Asia Pacific Biosimilars Market- By Country Market Share, 2021 & 2028
Figure 79: China Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 80: China Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 81: China Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 82: Japan Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 83: Japan Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 84: Japan Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 85: India Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 86: India Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 87: India Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 88: Middle East and North Africa Population (in Million), 2018-2020
Figure 89: Middle East & North Africa , Current health expenditure per capita (current USD), 2016-19
Figure 90: Prevalence of Cancer in Middle East & North Africa, (in million), 2015-2019
Figure 91: Middle East & North Africa , Current health expenditure per capita (% of GDP), 2016-19
Figure 92: MEA Biosimilars Market Size, By Value, 2018-2028 (USD Billion)
Figure 93: MEA Biosimilars Market- By Product Type, By Value (USD Billion), 2018-2028
Figure 94: MEA Biosimilars Market- By Application, By Value (USD Billion), 2018-2028
Figure 95: Market Attractiveness Chart of Global Biosimilars Market- By Product Type (Year-2028)
Figure 96: Market Attractiveness Chart of Global Biosimilars Market- By Application (Year-2028)
Figure 97: Market Attractiveness Chart of Global Biosimilars Market- By Region (Year-2028)
Figure 98: Global Biosimilars Market Share (%), 2021
Figure 99: Pfizer Limited, Sales Revenues, 2018-2021 (USD Billion)
Figure 100: Pfizer Limited, Net Earnings, 2018-2021 (USD Billion)
Figure 101: Pfizer Limited, By Business Segment (%), FY2021
Figure 102: Pfizer Limited, By Geographical Segment (%), FY2021
Figure 103: Dr. Reddyis Laboratories Sales Revenues, 2018-2021 (USD Billion)
Figure 104: Dr. Reddyis Laboratories Net Earnings, 2018-2021 (USD Billion)
Figure 105: Dr. Reddyis Laboratories, By Business Segment (%), FY2021
Figure 106: Dr. Reddyis Laboratories, By Business Segment (%), FY2020
Figure 107: Amgen Corporation Annual Sales Revenue, 2018-2021 (USD Million)
Figure 108: Amgen Corporation Net Earnings, 2018-2021 (USD Million)
Figure 109: Amgen Net Sales Revenue, By Business Segment (%), FY2021
Figure 110: Amgen Sales Revenue, By Geographic Segment (%), FY2021
Figure 111: Novartis AG Annual Sales Revenue, 2018-2021 (USD Million)
Figure 112: Novartis AG Net Earnings, 2018-2021 (USD Million)
Figure 113: Novartis AG Sales Revenue, By Business Segment (%), FY2021
Figure 114: Novartis AG Sales Revenue, By Geographical Segment (%), FY2021
Figure 115: Teva Pharmaceuticals Ltd., Annual Sales Revenue, 2018-2021 (USD Million)
Figure 116: Teva Pharmaceuticals Ltd., Net Earnings, 2018-2021 (USD Million)
Figure 117: Teva Pharmaceuticals Ltd., Sales Revenue, By Business Segment (%), FY2021
Figure 118: Teva Pharmaceuticals Ltd., Sales Revenue, By Geographical Segment (%), FY2021
Figure 119: Samsung Biologics, Annual Sales Revenue, 2018-2021 (USD Million)
Figure 120: Samsung Biologics, Net Earnings, 2018-2021 (USD Million)
Figure 121: Samsung Biologics, Sales Revenue, By Business Segment (%), FY2021
Figure 122: Samsung Biologics, Sales Revenue, By Geographic Segment (%), FY2021
Figure 123: Eli Lilly and company, Annual Sales Revenue, 2018-2021 (USD Million)
Figure 124: Eli Lilly and company, Net Earnings, 2018-2021 (USD Million)
Figure 125: Eli Lilly and company, Sales Revenue, By Business Segment (%), FY2021
Figure 126: Eli Lilly and company, Sales Revenue, By Geographic Segment (%), FY2021
Figure 127: Stada Arzneimittel AG Annual Sales Revenue, 2018-2021 (USD Million)
Figure 128: Stada Arzneimittel AG Net Earnings, 2018-2021 (USD Million)
Figure 129: Stada Arzneimittel AG Sales Revenue, By Business Segment (%), FY2021
Figure 120: Stada Arzneimittel AG Sales Revenue, By Geographical Segment (%), FY2021
Figure 131: Celltrion, Annual Sales Revenue, 2018-2021 (USD Billion)
Figure 132: Celltrion, Net Profit, 2018-2021 (USD Billion)
Figure 133: Biocon Limited, Annual Sales Revenue (USD Million), 2018-2021
Figure 134: Biocon Limited, Annual Net Earnings (USD Million), 2018-2021
Figure 135: Biocon Limited, Sales Revenue, By Business Segment (%), FY2021
Figure 136: Biocon Limited, Sales Revenue, By Geographical Segment (%), FY2021

Global Biosimilars Market (2022 Edition) - Analysis By Product Type, Application, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028)

Description

Table of Contents

List of Tables

Executive Summary

Scope of the Report

Key Target Audience

Table of Contents

1. Report Scope and Methodology

2. Strategic Recommendations

3. Global Biosimilars Market: Product Overview

4. Global Biosimilars Market: An Analysis

5. Global Biosimilars Market: Segment Analysis

6. Global Biosimilars Market: Segment Analysis By Application

7. Global Biosimilars Market: Regional Analysis

8. Americas Biosimilars Market: An Analysis (2018-2028)

9. Europe Biosimilars Market: An Analysis (2018-2028)

10. Asia Pacific Biosimilars Market: An Analysis (2018-2028)

11. MEA Biosimilars Market

12. Global Biosimilars Market Dynamics

13. Market Attractiveness and Strategic Analysis

14. Competitive Landscape

15. Company Profiles (Business Description, Financial Analysis, Business Strategy)

List of Figures

List of Figures